FR2381523A1 - USE OF 1,2-BUTANE-DIOL-1-METHYL ETHER AS A SOLVENT FOR PHARMACEUTICAL PREPARATIONS - Google Patents

USE OF 1,2-BUTANE-DIOL-1-METHYL ETHER AS A SOLVENT FOR PHARMACEUTICAL PREPARATIONS

Info

Publication number
FR2381523A1
FR2381523A1 FR7804393A FR7804393A FR2381523A1 FR 2381523 A1 FR2381523 A1 FR 2381523A1 FR 7804393 A FR7804393 A FR 7804393A FR 7804393 A FR7804393 A FR 7804393A FR 2381523 A1 FR2381523 A1 FR 2381523A1
Authority
FR
France
Prior art keywords
solvent
methyl ether
acetate
butane
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7804393A
Other languages
French (fr)
Other versions
FR2381523B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of FR2381523A1 publication Critical patent/FR2381523A1/en
Application granted granted Critical
Publication of FR2381523B1 publication Critical patent/FR2381523B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

L'éther 1,2-butane-diol-1-méthylique est utilisé comme solvant à des fins pharmaceutiques, en particulier pour des solutions injectables. On citera, à titre d'exemples de substances solubles dans ce solvant, dans des concentrations relativement élevées à la température ambiante : les hydantoïnes (diphénylhydantoïne), les benzodiazépines (diazépam, chlorodiazépoxyde), les dérivés de la pyrazolone (diphénylbutazone, aminophenazène, diméthylaminophénazène), les carbamates (méprobamate), les barbiturates (phénobarbital, pertobarbital, amobarbital), les antibiotiques (chloramphénicol, oxytétracycline), les sulfamides (sulfaméthoxazol, sulfamoxol, sulfathiazine), les stéroïdes (prednisolone, acétate de cyprotérone, capronate d'hydroxyprogestérone) ou les potentialisateurs de sulfamindes (triméthoprime); les vitamines liposolubles A, E et K et, le cas échéant, leurs dérivés, comme le palmitate, l'acétate ou le propionate de vitamine A, l'acétate ou le nicotinate de vitamine E, peuvent même être mélangés, dans n'importe quelles proportions, avec l'éther 1,2-butane-diol-1-méthylique.1,2-Butanediol-1-methyl ether is used as a solvent for pharmaceutical purposes, especially for injection solutions. As examples of substances soluble in this solvent, in relatively high concentrations at room temperature, we may cite: hydantoins (diphenylhydantoin), benzodiazepines (diazepam, chlorodiazepoxide), pyrazolone derivatives (diphenylbutazone, aminophenazene, dimethylaminophenazene) ), carbamates (meprobamate), barbiturates (phenobarbital, pertobarbital, amobarbital), antibiotics (chloramphenicol, oxytetracycline), sulfonamides (sulfamethoxazol, sulfamoxol, sulfathiazine), steroids (prednisoloneproxone), cyogyroxy acetate or sulfonamind potentiators (trimethoprim); fat-soluble vitamins A, E and K and, where appropriate, their derivatives, such as vitamin A palmitate, acetate or propionate, vitamin E acetate or nicotinate, can even be mixed, in any what proportions, with 1,2-butanediol-1-methyl ether.

FR7804393A 1977-02-26 1978-02-16 USE OF 1,2-BUTANE-DIOL-1-METHYL ETHER AS A SOLVENT FOR PHARMACEUTICAL PREPARATIONS Granted FR2381523A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19772708419 DE2708419C3 (en) 1977-02-26 1977-02-26 Use of 1,2-butanediol methyl ether as a solvent for pharmaceutical injection solutions

Publications (2)

Publication Number Publication Date
FR2381523A1 true FR2381523A1 (en) 1978-09-22
FR2381523B1 FR2381523B1 (en) 1982-10-22

Family

ID=6002245

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7804393A Granted FR2381523A1 (en) 1977-02-26 1978-02-16 USE OF 1,2-BUTANE-DIOL-1-METHYL ETHER AS A SOLVENT FOR PHARMACEUTICAL PREPARATIONS

Country Status (6)

Country Link
BE (1) BE864206A (en)
CH (1) CH633181A5 (en)
DE (1) DE2708419C3 (en)
FR (1) FR2381523A1 (en)
GB (1) GB1593354A (en)
NL (1) NL7801277A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035132A2 (en) * 1980-02-07 1981-09-09 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pharmaceutic preparations with glycerine-alkyl ethers and the use of the latter as pharmaceutical solvents

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19611624C2 (en) * 1996-03-25 1999-02-25 Henkel Kgaa Cosmetic and / or pharmaceutical preparations
WO2016038626A1 (en) * 2014-09-12 2016-03-17 Emcure Pharmaceuticals Limited Pharmaceutical compositions of vitamin kl
US20230200380A1 (en) * 2020-04-30 2023-06-29 Evonik Operations Gmbh Use of polyethers as carrier for active ingredients

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035132A2 (en) * 1980-02-07 1981-09-09 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Pharmaceutic preparations with glycerine-alkyl ethers and the use of the latter as pharmaceutical solvents
EP0035132A3 (en) * 1980-02-07 1982-09-29 F. Hoffmann-La Roche & Co. Aktiengesellschaft Pharmaceutic preparations with glycerine-alkyl ethers and the use of the latter as pharmaceutical solvents

Also Published As

Publication number Publication date
DE2708419A1 (en) 1978-08-31
DE2708419B2 (en) 1978-12-21
GB1593354A (en) 1981-07-15
NL7801277A (en) 1978-08-29
FR2381523B1 (en) 1982-10-22
CH633181A5 (en) 1982-11-30
DE2708419C3 (en) 1979-08-16
BE864206A (en) 1978-08-22

Similar Documents

Publication Publication Date Title
KR0135313B1 (en) Topical metronidazole formulation
US5587149A (en) Topical application emulsions
EP0481007B1 (en) SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US6258830B1 (en) Stable gel formulation for topical treatment of skin conditions
US5834022A (en) Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
DZ1078A1 (en) Pharmaceutical formulation of acid labile substance for oral administration.
AU570639B2 (en) Corticoid topical formulation
CH652307A5 (en) PHARMACEUTICAL COMPOSITION FOR ORAL USE.
JPS6323971B2 (en)
JPS63174922A (en) Oral therapy system
CZ291211B6 (en) Topically applicable pharmaceutical composition, process of its preparation and use
DE10154324A1 (en) Topically applicable compositions with external active substance depot formation, their production and their use
FR2647343A1 (en) NOVEL POROUS PHARMACEUTICAL FORM AND PREPARATION THEREOF
US4832952A (en) Pharmaceutical composition containing a liquid lubricant
FR2381523A1 (en) USE OF 1,2-BUTANE-DIOL-1-METHYL ETHER AS A SOLVENT FOR PHARMACEUTICAL PREPARATIONS
KR950015063B1 (en) Water-containing external preparation
JP2879905B2 (en) Composition for oral administration containing ibuprofen
FR2363324A1 (en) AQUEOUS OR HYDROALCOOLIC STABLE SOLUTIONS OF PERFUMED ESSENCES OR OIL SOLUBLE MEDICINAL PRODUCTS
JPH0413624A (en) Pyroxycam-containing pharmaceutical composition for topical application
JP3214105B2 (en) Cross-linked hap base
JP3280071B2 (en) Anti-inflammatory analgesic external preparation
WO1993024129A1 (en) Composition for treating acne vulgaris
JP2906269B2 (en) External preparation for skin
WO2001047525A1 (en) Antipruritic agents for external use
RU2157683C2 (en) Anti-inflammatory preparation for topical use

Legal Events

Date Code Title Description
ST Notification of lapse